JP2015529641A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529641A5
JP2015529641A5 JP2015521849A JP2015521849A JP2015529641A5 JP 2015529641 A5 JP2015529641 A5 JP 2015529641A5 JP 2015521849 A JP2015521849 A JP 2015521849A JP 2015521849 A JP2015521849 A JP 2015521849A JP 2015529641 A5 JP2015529641 A5 JP 2015529641A5
Authority
JP
Japan
Prior art keywords
seq
antibody
tumor
variable region
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015521849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529641A (ja
JP6335896B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050300 external-priority patent/WO2014012007A2/en
Publication of JP2015529641A publication Critical patent/JP2015529641A/ja
Publication of JP2015529641A5 publication Critical patent/JP2015529641A5/ja
Application granted granted Critical
Publication of JP6335896B2 publication Critical patent/JP6335896B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015521849A 2012-07-13 2013-07-12 Ｒｓｐｏ３結合剤およびその使用法 Expired - Fee Related JP6335896B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261671421P 2012-07-13 2012-07-13
US61/671,421 2012-07-13
US201361753184P 2013-01-16 2013-01-16
US61/753,184 2013-01-16
US201361789156P 2013-03-15 2013-03-15
US61/789,156 2013-03-15
US201361826747P 2013-05-23 2013-05-23
US61/826,747 2013-05-23
PCT/US2013/050300 WO2014012007A2 (en) 2012-07-13 2013-07-12 Rspo3 binding agents and uses thereof

Publications (3)

Publication Number Publication Date
JP2015529641A JP2015529641A (ja) 2015-10-08
JP2015529641A5 true JP2015529641A5 (cg-RX-API-DMAC7.html) 2016-09-01
JP6335896B2 JP6335896B2 (ja) 2018-05-30

Family

ID=49914164

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521849A Expired - Fee Related JP6335896B2 (ja) 2012-07-13 2013-07-12 Ｒｓｐｏ３結合剤およびその使用法

Country Status (24)

Country Link
US (3) US9181333B2 (cg-RX-API-DMAC7.html)
EP (1) EP2872175A4 (cg-RX-API-DMAC7.html)
JP (1) JP6335896B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150036603A (cg-RX-API-DMAC7.html)
CN (1) CN104854132A (cg-RX-API-DMAC7.html)
AU (1) AU2013289990B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000776A2 (cg-RX-API-DMAC7.html)
CA (1) CA2878868A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015000097A1 (cg-RX-API-DMAC7.html)
EA (1) EA032038B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15005280A (cg-RX-API-DMAC7.html)
HK (1) HK1208687A1 (cg-RX-API-DMAC7.html)
IL (1) IL236617A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00350A (cg-RX-API-DMAC7.html)
MX (1) MX2015000565A (cg-RX-API-DMAC7.html)
NI (1) NI201500002A (cg-RX-API-DMAC7.html)
NZ (1) NZ704269A (cg-RX-API-DMAC7.html)
PE (1) PE20150360A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500084A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201500233PA (cg-RX-API-DMAC7.html)
TW (2) TWI636061B (cg-RX-API-DMAC7.html)
UA (1) UA117659C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014012007A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500872B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
JP6335896B2 (ja) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ３結合剤およびその使用法
TWI658052B (zh) * 2013-10-18 2019-05-01 美商建南德克公司 抗－ｒｓｐｏ抗體及使用方法
BR112017000130A2 (pt) 2014-07-11 2018-01-09 Genentech Inc método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
MA41123A (fr) * 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer
WO2017040660A1 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CN106913880B (zh) * 2015-12-24 2021-02-12 上海交通大学 一种含有rspo1的靶向给药系统及其制备与应用
CN105925576B (zh) * 2016-03-24 2018-04-20 嘉兴市第一医院 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用
US20170319688A1 (en) * 2016-04-14 2017-11-09 Genentech, Inc. Anti-rspo3 antibodies and methods of use
WO2018035210A1 (en) * 2016-08-17 2018-02-22 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with an rspo antagonist
KR102762570B1 (ko) * 2017-12-07 2025-02-06 내셔날 헬스 리서치 인스티튜트 항-rspo3 항체
CN110339364B (zh) * 2018-04-02 2021-02-12 上海邦耀生物科技有限公司 Lgr4/rspo阻断剂与抗免疫检查点抑制剂联合用于肿瘤的免疫治疗
CN110467663B (zh) * 2019-06-18 2022-05-10 华南农业大学 Rspo3基因在母猪卵巢颗粒细胞中的应用
WO2021123198A1 (en) * 2019-12-19 2021-06-24 Deutsches Krebsforschungszentrum Leukemia treatment
KR102554222B1 (ko) * 2023-03-21 2023-07-11 순천향대학교 산학협력단 신규한 항-인간 알스폰딘3 항체 및 이의 용도
CN116769030B (zh) * 2023-08-21 2023-10-20 成都大熊猫繁育研究基地 一种大熊猫松弛素3单克隆抗体及其杂交瘤细胞株和应用

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US20070124581A1 (en) 1992-05-17 2007-05-31 Reena Khare Cell adhesion and extracellular matrix proteins
EP0977853A1 (en) 1997-04-25 2000-02-09 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
JP2001517441A (ja) 1997-09-24 2001-10-09 メルク エンド カムパニー インコーポレーテッド Ｇタンパク質共役糖タンパク質ホルモン受容体ｈｇ３８
US20020065394A1 (en) 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
ES2332025T3 (es) 1998-03-26 2010-01-22 The Board Of Trustees Of The Leland Stanford Junior University Nuevos receptores de mamiferos acoplados a la proteina g que tienen regiones extracelulares de repeticion ricas en leucina.
US6485972B1 (en) 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
US20030166047A1 (en) 1999-05-06 2003-09-04 Millennium Pharmaceuticals, Inc. Lgr6 nucleic acids and uses thereof
WO2001007611A2 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
EP1267616B1 (en) 2000-03-31 2007-08-08 The General Hospital Corporation Methods of increasing hair growth by wnt polypeptide
WO2001077169A2 (en) 2000-04-05 2001-10-18 Kirin Beer Kabushiki Kaisha Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
EP1156062A1 (en) 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
AU2001263006A1 (en) 2000-05-18 2001-11-26 Hyseq, Inc. Novel nucleic acids and polypeptides
US20030139341A1 (en) 2000-05-30 2003-07-24 Shyam Ramakrishnan Regulation of human lgr4-like g protein -coupled receptor
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
US20040077048A1 (en) 2002-01-30 2004-04-22 Warren Bridget A. Protein modification and maintenance molecules
US7411052B2 (en) 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20100292155A1 (en) 2001-03-05 2010-11-18 Arca Biopharma, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030032034A1 (en) 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2003029405A2 (en) 2001-08-30 2003-04-10 Nuvelo Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
AU2002304249A1 (en) 2001-06-11 2002-12-23 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030022217A1 (en) 2001-07-02 2003-01-30 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US20050130145A1 (en) 2001-10-03 2005-06-16 Henry Yue Secreted proteins
US20070237770A1 (en) * 2001-11-30 2007-10-11 Albert Lai Novel compositions and methods in cancer
US20040197778A1 (en) 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
JP2005511754A (ja) 2001-12-07 2005-04-28 リージェンツ オブ ザ ユニバーシティ オブ ミシガン 乳癌幹細胞の予測的同定および特徴づけ
EP1504099A4 (en) 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
WO2003091280A1 (en) 2002-04-26 2003-11-06 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004074436A2 (en) 2003-02-19 2004-09-02 Incyte Corporation Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
US20050003405A1 (en) 2003-04-30 2005-01-06 Hua-Chien Chen Treatment and diagnostics of cancer
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005110009A2 (en) 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
DE10339820A1 (de) 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Verwendung von an GPR49 bindenden Substanzen zur Diagnose und Behandlung von Krebs
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
ES2345256T3 (es) 2003-10-10 2010-09-20 Deutsches Krebsforschungszentrum Composiciones para diagnosis y terapia de enfermedades asociadas con la expresion aberrante de futrinas (r-espondinas) y/o wnt.
WO2005040828A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
CA2554403A1 (en) 2004-01-27 2005-08-11 Nuvelo, Inc. Gastrointestinal proliferative factor and uses thereof
JP2007526455A (ja) 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
MX2007002883A (es) 2004-09-13 2007-06-15 Macrogenics Inc Anticuerpos humanizados contra el virus de nilo occidental y usos terapeuticos y profilacticos del mismo.
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7439327B2 (en) 2005-01-18 2008-10-21 Nuvelo, Inc. Stem cell factor-like proteins and uses thereof
EP1910557A2 (en) 2005-04-07 2008-04-16 Chiron Corporation Cancer-related genes
US20090036369A1 (en) 2005-07-26 2009-02-05 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
WO2007030290A2 (en) 2005-09-07 2007-03-15 Maine Medical Center Research Cristin/r-spondin ligands active in the wnt signaling pathway and methods, compositions and kits relating thereto
WO2007100357A2 (en) 2005-10-07 2007-09-07 Nuvelo, Inc. Stem cell factor-like protein scfa1 and uses thereof
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
NZ573818A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
NZ573819A (en) 2006-06-02 2011-09-30 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
EP2032166B1 (en) 2006-06-13 2013-04-10 OncoMed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
KR101528939B1 (ko) * 2006-07-18 2015-06-15 사노피 암 치료를 위한 ｅｐｈａ2에 대한 길항제 항체
JP2008044926A (ja) 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
EP2081586B2 (en) 2006-10-20 2018-10-31 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Rspondins as modulators of angiogenesis and vasculogenesis
WO2008075796A1 (ja) 2006-12-21 2008-06-26 Kyowa Hakko Kirin Co., Ltd. 血球回復促進剤
WO2008088524A2 (en) 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
AU2008266952A1 (en) 2007-06-12 2008-12-24 Trubion Pharmaceuticals, Inc. Anti-CD20 therapeutic compositions and methods
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
AU2008307544A1 (en) 2007-10-02 2009-04-09 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
JP5676107B2 (ja) 2007-11-14 2015-02-25 中外製薬株式会社 抗ｇｐｒ４９抗体を用いる癌の診断および治療
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
WO2010016766A2 (en) 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
RU2521669C2 (ru) * 2008-10-31 2014-07-10 Торэй Индастриз, Инк. Способ иммунологического анализа белка cxcl1 человека
EP2419133A1 (en) 2009-04-15 2012-02-22 Deutsches Krebsforschungszentrum Rspondin-3 inhibition in bone disorders
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2010129284A1 (en) 2009-04-27 2010-11-11 The Trustees Of The University Of Pennsylvania Inhibition of hair follicle growth by the wnt inhibitor dkk1
WO2010148337A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
US8318162B2 (en) * 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
IN2012DN01920A (cg-RX-API-DMAC7.html) 2009-09-03 2015-07-24 Schering Corp
EP2977060A1 (en) 2009-12-23 2016-01-27 Deutsches Krebsforschungszentrum Receptors of rspo2 and rspo3
WO2011085289A1 (en) 2010-01-11 2011-07-14 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Production of a monoclonal antibody therapeutic against west nile virus in plants
JP6034696B2 (ja) 2010-02-12 2016-11-30 オンコメッド ファーマシューティカルズ インコーポレイテッド ポリペプチド発現細胞の同定及び単離の方法
EP2659005A4 (en) 2010-12-28 2016-08-24 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
US9803026B2 (en) * 2011-04-28 2017-10-31 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
ES2769786T3 (es) 2011-10-14 2020-06-29 Recordati Ag Anticuerpos y métodos para enfermedades relacionadas con la vía Wnt
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
EP2773664A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
JP6335896B2 (ja) 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ３結合剤およびその使用法
JP2016518328A (ja) 2013-03-12 2016-06-23 キュアジェニックス インコーポレイテッド 癌治療のための化合物
CA2913924A1 (en) 2013-05-30 2014-12-04 Order-Made Medical Research Inc. Reagent including anti-lgr6 antibodies for detection and diagnosis of cancer
TWI658052B (zh) 2013-10-18 2019-05-01 美商建南德克公司 抗－ｒｓｐｏ抗體及使用方法
US9777052B2 (en) 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
MA41123A (fr) 2014-12-02 2017-10-10 Oncomed Pharm Inc Polythérapie pour le traitement du cancer

Similar Documents

Publication Publication Date Title
JP2015529641A5 (cg-RX-API-DMAC7.html)
JP2014524746A5 (cg-RX-API-DMAC7.html)
JP6872537B2 (ja) 抗ｌａｇ３抗体およびその使用
WO2014012007A4 (en) Rspo3 binding agents and uses thereof
AU2015240599B2 (en) Humanized antibodies that bind LGR5
RU2014101669A (ru) Агенты, связывающие белки r-спондины (rspo), и способы их применения
CN106573977B (zh) 针对ceacam1的人源化抗体
HRP20150256T1 (hr) Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
RU2011115117A (ru) Нацеленные средства связывания, направленные на dll4, и их применение
JP2016187356A5 (cg-RX-API-DMAC7.html)
JP2010518820A5 (cg-RX-API-DMAC7.html)
JP2013502913A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
JP2010532169A5 (cg-RX-API-DMAC7.html)
JP2018503365A5 (cg-RX-API-DMAC7.html)
JP2016128474A5 (cg-RX-API-DMAC7.html)
JP2013527761A5 (cg-RX-API-DMAC7.html)
JP2012501626A5 (cg-RX-API-DMAC7.html)
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
JP2015506912A5 (cg-RX-API-DMAC7.html)
CN109311978B (zh) Dsg2单克隆抗体和其用途
JP2012525149A5 (cg-RX-API-DMAC7.html)
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2012523848A5 (cg-RX-API-DMAC7.html)
JP2012503990A5 (cg-RX-API-DMAC7.html)